Life Sciences weekly highlights—12 March 2026
This week's edition of Life Sciences weekly highlights includes news that the EMA has published draft guidance from the Accelerating Clinical Trials in the EU (ACT EU) initiative on the conduct of clinical trials during public health emergencies, the MHRA has published and updated several key guidance documents ahead of amendments to the new UK clinical trials regulations and has announced the publication of a new analysis on the global impact of UK health data resource. Also included, is news that MedTech Europe has commented on the EU–US trade framework and the development on US tariff measures, and has also joined an industry statement calling for harmonised rules under the Circular Economy Act, the European Commission and Switzerland have signed a broad package of agreements to simplify trade in goods such as medical devices, Medicines for Europe has urged stronger supply security measures in Critical Medicines Act trilogues, the Commission has identified safety and labelling non-compliance in dermal fillers, the Association of the British Pharmaceutical Industry (ABPI) has outlined outcomes of the December 2025 VPAG review, the Department of Health and Social Care (DHSC) has completed its review of the genetic testing and insurance code, and the UK Space Agency, the MHRA, the Regulatory Innovation Office (RIO) and the Civil Aviation Authority (CAA) have announced a collaborative effort to develop a regulatory framework for in-orbit pharmaceutical manufacturing, among other stories.